Targovax granted US Patent for mutant-RAS neoantigen platform lead products
Extends IP protection of TG01 and TG02 until 06.05.2034Oslo, 25 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the US Patent and Trademark Office has granted US Patent no 9,757,439. The patent protects Targovax' mutant-RAS specific neoantigen vaccines, TG01 and TG02, for the treatment of cancer in combination with anti-metabolite chemotherapy. Jon Amund Eriksen, Chief Technology Innovation Officer, and Co-founder of Targovax, said: "We are delighted